Ubi^{select}™-MEF_BirA (P0)

Cat. No. **66-5010-001**
Lot. No. **30346**

Quantity: $2.5x10^6$ cells
Storage: Cryopreserved

FOR RESEARCH USE ONLY

NOT FOR USE IN HUMANS

Background

The post-translational modification of proteins by ubiquitin is involved in a wide range of cellular processes (Kirkin and Dikic, 2007). In any given cell the proportion of protein modified by ubiquitin is very small therefore it has been difficult to isolate and identify this post translational modification from mammalian whole cell lysates. Ubiquitin proteomics remains challenging even though the sensitivity of Mass Spectrometry (MS) has improved dramatically through the use of innovative techniques (Sylvestersen *et al.*, 2013). Various approaches employing tagged ubiquitin or ubiquitin like molecules have been used with varying degrees of success (Peng *et al.*, 2003; Tirard *et al.*, 2012; Tsirigotis *et al.*, 2001). In recent years, the isolation of ubiquitylated proteins from neurons of *Drosophila melanogaster* using a tagged ubiquitin with a 15 amino acid long biotin-accepting peptide has been described (Franco *et al.*, 2011). This was the first demonstration that proteomics could be used to identify neuronal targets of the ubiquitin-proteasome system. This novel technique allowed for the isolation and enrichment of ubiquitin conjugates from neurons using a relatively small sample up to levels that allowed direct detection by MS and Western blotting. In addition, diglycine signatures indicative of the ubiquitin attachment sites could also be detected on ubiquitin conjugates. Where antibodies were available for specific ubiquitin proteasome system substrates it was also possible to determine whether a substrate was

Continued on page 2

Culture Characteristics

Species: mouse

Source: mouse embryonic fibroblasts

Quantity: $2.5x10^6$ cells in 1 ml 90% fetal bovine serum (FBS), 10% DMSO

Culture Medium: DMEM high glucose (HG), 200 mM L-glutamine, 100 mM sodium pyruvate, 10% FBS, biotin 0.2 µg/mL, 1x pen/strep

Growth Mode: adherent

Passage Number: passage 0

Storage: cryopreserved

Culture Conditions: Thaw the cells by swirling the vial in a 37°C waterbath. Place 5 ml of culture media into a T25 flask and pipette cells into the flask containing the media. Place the T25 flask containing the cells into a 37°C 5% CO_2 incubator overnight and replace with fresh media the next morning.

Recommended sub-culture routine: When the Ubi^{select}-MEF_BirA cells reach confluency, aspirate culture media from the T25 flask and rinse cells with 5 ml PBS. Aspirate the PBS from the T25 flask and add 1 ml 0.05% Trypsin-EDTA (1x). Incubate the BirA MEF cells in a 37°C 5% CO_2 incubator for a few minutes until the cells begin to detach, knock the side of the flask to fully detach the cells, neutralise with 4 ml of media and collect in a 15 ml tube then count the cells. Seed the Ubi^{select}-MEF_BirA cells in T75 flasks at 1.2×10^4 cells/cm^2 (i.e. $9x10^5$ cells per T75 flask) and place in a 37°C 5% CO_2 incubator and grow until confluency (P1). Re-feed the Ubi^{select}-MEF_BirA cells the morning after plating then every 3-4 days and passage as required until harvest.

Description of Transgene: This is a hemizygous cell line derived from a transgenic mouse expressing the *E. coli* enzyme BirA Accession number: [P06709.1] (Lectez *et al.*, 2014).

BirA hemizygous transgene (2952bp insert)

Quality Assurance

Mycoplasma: Not detected

Morphology: Fibroblast

Viability (%): ≥95

Activity: For representative Ubi^{select}-MEF_BirA cell line activity data, please refer to the Ubi^{select}™ Kit application note (Application Note number 004).

www.ubiquigent.com
Dundee, Scotland, UK

ORDERS / SALES SUPPORT
International: +1-617-245-0020
US Toll-Free: 1-888-4E1E2E3 (1-888-431-3233)
Email: sales.support@ubiquigent.com

UK HQ and TECHNICAL SUPPORT
International: +44 (0) 1382 381147 (9AM-5PM UTC)
US/Canada: +1-617-245-0020 (9AM-5PM UTC)
Email: tech.support@ubiquigent.com

Email **services@ubiquigent.com** for enquiries regarding compound profiling and/or custom assay development services.

© Ubiquigent 2014. Unless otherwise noted, Ubiquigent, Ubiquigent logo and all other trademarks are the property of Ubiquigent, Ltd.

Limited Terms of Use: For research use only. Not for use in humans or for diagnostics. Not for distribution or resale in any form, modification or derivative OR for use in providing services to a third party (e.g. screening or profiling) without the written permission of Ubiquigent, Ltd.

Lot-specific COA version tracker: v1.0.0

Ubi^{select}™-MEF_BirA (P0)

Cat. No. **66-5010-001**
Lot. No. **30346**

Quantity: $2.5\text{x}10^6$ cells
Storage: Cryopreserved

FOR RESEARCH USE ONLY

NOT FOR USE IN HUMANS

Background

Continued from page 1

mono- or polyubiquitylated (Franco *et al.*, 2011). Using a similar approach, a hemizygous BirA control transgenic mouse has been created whose transgene expresses the *E. coli* enzyme BirA only (Lectez *et al.*, 2014). The BirA enzyme recognises and biotinylates sequences carrying the Biotinylation Acceptor Peptide (BAP) sequence (see Cat# 66-5011-001 and Application Note 004 for details). Ubi^{select}-MEF_BirA (Cat# 66-5010-001) has been derived from 13.5 day old embryos of this transgenic mouse line by homogenisation and trypsinisation of embryos minus the head and liver. Ubi^{select}-MEF_BirA may be used as a negative control in experiments also employing Ubi^{select}-MEF_Bio-Ub (P0) (Cat# 66-5011-001) in experiments to efficiently capture ubiquitylated proteins from treated and untreated MEF cells for analysis; see Application Note 004 for details. By using cell and tissue lysates derived from Bio-Ub transgenic mice it has been possible to isolate ubiquitylated proteins from ubiquitylated protein binding proteins (Lectez *et al.*, 2014). The specific isolation of ubiquitylated proteins is achieved through the high affinity interaction between biotin and avidin and high stringency washing which allows for the removal of interacting partners of ubiquitylated proteins which would otherwise predominate under the milder washing conditions of alternative ubiquitin capture systems. Using lysates prepared from Bio-Ub expressing liver tissue, the isolation of ubiquitin conjugated proteins (both thioester and isopeptide linked) has been demonstrated, therefore this is the first mammalian system for ubiquitin proteomics which allows for the direct detection of captured proteins by MS and Western blotting. Isolation of ubiquitylated proteins from Ubi^{select}-MEF_Bio-Ub has also been demonstrated (see Application Note 004) and it is anticipated that this technology will enable researchers to gain a better understanding of the functioning of ubiquitin system signalling.

References:

Franco M, (2011) A novel strategy to isolate ubiquitin conjugates reveals wide role for ubiquitination during neural development. *Mol Cell Proteomics* **10**, M110 002188.

Kirkin V and Dikic I. (2007) Role of ubiquitin- and Ubl-binding proteins in cell signaling. *Curr Opin Cell Biol* **19**, 199-205.

Lectez B, Migotti R, Lee SY, Ramirez J, Beraza N, Mansfield B, Sutherland JD, Martinez-Chantar ML, Dittmar G, Mayor U. (2014) Ubiquitin Profiling in Liver Using a Transgenic Mouse with Biotinylated Ubiquitin. *J Proteome Res* Apr 30 [Epub ahead of print].

Peng J, Schwartz D, Elias J E, Thoreen C C, Cheng D, Marsischky G, Roelofs J, Finley D, Gygi SP (2003) A proteomics approach to understanding protein ubiquitination. *Nat Biotechnol* **21**, 921-926.

Sylvestersen K B, Young C, Nielsen M L. (2013) Advances in characterizing ubiquitylation sites by mass spectrometry. *Curr Opin Chem Biol* **17**, 49−58.

Tirard M, Hsiao H H, Nikolov M, Urlaub H, Melchior F, Brose N. (2012) In vivo localization and identification of SUMOylated proteins in the brain of His6-HA-SUMO1 knock-in mice. *Proc Natl Acad Sci U S A* **109**, 21122-21127.

Tsirigotis M, Thurig S, Dube M, Vanderhyden BC, Zhang M, Gray DA (2001) Analysis of ubiquitination *in vivo* using a transgenic mouse model *Biotechniques* **31**, 120-126.

Limited Use Licence
(in respect of product Cat# 66-5010-001)

The technology used to derive the cell line(s) described in this document is owned by CIC bioGUNE and exclusively licenced for commercialisation by Ubiquigent Ltd.

The Biotin AviTag technology is covered by U.S. Pat. Nos: 5,723,584; 5,874,239; 5,932,433; and 6,265,552 and includes any and all materials, methods, kits and related derivatives claimed by these patents. The purchase of the UBIQUIGENT's AviTagged products confers to the purchaser the limited right to use the AviTag™ technology for research use.

Commercial use of the AviTag™ technology to manufacture a commercial product, or use of the AviTag™ technology to facilitate or advance research which will be applied to the development of a commercial product requires a license from Avidity, LLC. Examples of Commercial use include, but are not limited to biosensors, diagnostics, therapeutic applications, proximity assays, and drug screening assays. Users desiring a commercial license should contact Avidity, LLC in the US @ 720-859-6111 or by email to Lansing@avidity.com.

ORDERS / SALES SUPPORT

International: +1-617-245-0020
US Toll-Free: 1-888-4E1E2E3 (1-888-431-3233)
Email: sales.support@ubiquigent.com

UK HQ and TECHNICAL SUPPORT

International: +44 (0) 1382 381147 (9AM-5PM UTC)
US/Canada: +1-617-245-0020 (9AM-5PM UTC)
Email: tech.support@ubiquigent.com

Email **services@ubiquigent.com** for enquiries regarding compound profiling and/or custom assay development services.

© Ubiquigent 2014. Unless otherwise noted, Ubiquigent, Ubiquigent logo and all other trademarks are the property of Ubiquigent, Ltd.

Limited Terms of Use: For research use only. Not for use in humans or for diagnostics. Not for distribution or resale in any form, modification or derivative OR for use in providing services to a third party (e.g. screening or profiling) without the written permission of Ubiquigent, Ltd.

Lot-specific COA version tracker: v1.0.0